Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

ipharmaservices
Jul 10, 2023
0 min read

Recent Posts

Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter

Amgen has secured European Commission clearance for Uplizna (inebilizumab) as an add‑on therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti‑acetylcholine receptor (A

GSK’s ultra‑long‑acting IL‑5 biologic Exdensur wins EU approval for severe asthma and CRSwNP | iPharmaCenter

Exdensur (depemokimab), GSK’s new ultra‑long‑acting anti‑IL‑5 biologic, has been granted marketing authorisation by the European Commission for two respiratory indications: severe asthma driven by typ

GSK’s RSV Vaccine, Arexvy is now approved for all adults in Europe | iPharmaCenter

iPharmaCenter

ipharmacenter Consulting services

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Recent Posts

Comments